# US 11,999,955 B2 · Compositions and methods of treating facioscapulohumeral muscular dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,955 B2
- Document ID: US11999955B2
- Status: Granted
- Kind: B2
- Application number: 18/052,898
- Filed: 2022-11-04
- Published: 2023-10-26
- Granted: 2024-06-04
- Earliest claimed: 2020-03-19
- Assignees: Avidity Biosciences, Inc.
- Applicants: Avidity Biosciences, Inc.
- Inventors: Barbora Malecova; Rob Burke; David Sala Cano; Beatrice Diana Darimont
- Web page: https://patentgrep.com/patent/US11999955B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- C07K 16/2881: {against CD71}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/55: Fab or Fab'
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/31: of the backbone
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/332: Abasic residue
- C12N 2310/3513: Protein; Peptide
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/35: based on a specific dosage / administration regimen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

## Claims

### Claim 1

A polynucleotide-antibody conjugate comprising an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to a polynucleotide, wherein the polynucleotide is from 19 to 30 nucleotides in length, wherein the polynucleotide comprises a nucleic acid sequence selected from a group consisting of SEQ ID NOs: 72, 76, 126, 131, 132, 134, 135, 136, 212, 216, 266, 271, 272, 274, 275, and 276 and wherein the polynucleotide mediates RNA interference against DUX4 mRNA and downregulation of DUX4 biomarker mRNA level.

### Claim 2 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide is a single stranded polynucleotide.

### Claim 3 (depends on 2)

The polynucleotide-antibody conjugate of claim 2, wherein the single stranded polynucleotide is an antisense oligonucleotide (ASO) or a phosphorodiamidate morpholino oligomers (PMO).

### Claim 4 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the anti-transferrin receptor antibody or antigen binding fragment thereof binds to a transferrin receptor on a cell surface of a muscle cell.

### Claim 5 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide comprises at least one 2′ modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety.

### Claim 6 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide hybridizes to at least 8 contiguous bases of the target sequence of a human DUX4 mRNA.

### Claim 7 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide is from 19 to 25 nucleotides in length.

### Claim 8 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide-antibody conjugate comprises a linker connecting the anti-transferrin receptor antibody or antigen binding fragment thereof to the polynucleotide.

### Claim 9 (depends on 5)

The polynucleotide-antibody conjugate of claim 5, wherein the at least one 2′ modified nucleotide comprises 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl, 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-ODMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), 2′-O—N-methylacetamido (2′-O-NMA) modified nucleotide, locked nucleic acid (LNA), ethylene nucleic acid (ENA), or a combination thereof.

### Claim 10 (depends on 5)

The polynucleotide-antibody conjugate of claim 5, wherein the at least one modified internucleotide linkage comprises a phosphorodithioate linkage.

### Claim 11 (depends on 5)

The polynucleotide-antibody conjugate of claim 5, wherein the polynucleotide comprises three or more 2′ modified nucleotides selected from 2-O-methyl modified nucleotide and 2′-deoxy-2′-fluoro modified nucleotide.

### Claim 12 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide-antibody conjugate has a polynucleotide to antibody ratio from 1 to 4.

### Claim 13 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide comprises a 5′-terminal vinylphosphonate modified nucleotide.

### Claim 14 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the polynucleotide-antibody conjugate is formulated for parenteral administration.

### Claim 15 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the downregulation of DUX4 biomarker mRNA level is evaluated by expression level of one or more DUX4 biomarker genes selected from a group consisting of MBD3L2, TRIM43, PRAMEF1, ZSCAN4, KHDC1L, and LEUTX.

### Claim 16 (depends on 1)

The polynucleotide-antibody conjugate of claim 1, wherein the anti-transferrin receptor antibody or antigen binding fragment thereof is conjugated to the 5′ end of the polynucleotide.
